Skip to main content
Premium Trial:

Request an Annual Quote

UK Research Council Sets Aside $26M to Fund Chemical Genetics, Metabolomics

NEW YORK, Jan. 14 (GenomeWeb News) - The UK's Biotechnology and Biological Sciences Research Council this week announced two new funding opportunities in the areas of chemical genetics and metabolomics.


Under the "Selective Chemical Intervention in Biological Systems" initiative, a new program funded with with £10 million ($18.7 mllion), BBSRC will fund projects in the area of chemical genetics for up to five years  The deadline for the first round of applications is March 2.


BBSRC is also seeking proposals for the second phase of its "Plant and Microbial Metabolomics" initiative, providing funding of up to £4 million in total for three-year projects that will apply metabolomic approaches to relevant biological questions about plants or microorganisms. Applications have to be submitted by April 13.


BBSRC is one of seven research councils in the UKdistributing government funding for scientific research.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.